Aging US
Methylene blue guards hair stem cells against GLP-1 stress
Clinical Takeaway: The findings offer a possible mechanistic hook for emerging reports of GLP-1-associated hair loss, but do not support use in this indication.
Reports of hair thinning in patients on GLP-1 receptor agonists have started to surface alongside the rapid uptake of semaglutide and tirzepatide for weight management. The mechanism is unclear, and there are no targeted protective strategies. This study tested whether methylene blue, an FDA-approved drug with established antioxidant properties, could protect hair follicle stem cells from GLP-1-related stress in vitro.
Social media interest in methylene blue has surged. Wellness influencers tout it for energy, focus, anti-aging, and longevity. Its FDA approval is narrow: treatment of methemoglobinemia and use as a surgical dye. Other clinical uses, including in malaria and septic shock, are off-label.
In cultured human hair follicle stem cells, methylene blue increased proliferation and viability, reduced reactive oxygen species, and activated β-catenin signaling, a central pathway in hair regeneration. Scratch-assay experiments showed faster wound closure with treatment. When cells were exposed to escalating GLP-1 receptor agonist concentrations, viability fell in a dose-dependent pattern consistent with metabolic stress. Pretreatment with methylene blue for one week largely preserved viability, including at the highest concentration tested.
Combinations with other compounds yielded mixed results. Vitamins A and C added antioxidant capacity but unexpectedly suppressed methylene blue's β-catenin activation, suggesting these popular hair-and-skin antioxidants may work against the regenerative pathway when paired. Minoxidil, the standard topical for androgenetic alopecia, synergized with methylene blue to amplify β-catenin signaling and stem cell viability beyond either agent alone.
The corresponding author founded Mblue Labs, a methylene blue commercial venture.
Whether methylene blue at any clinically feasible dose would reach hair follicle stem cells in the scalp at concentrations sufficient to produce the observed effects is unknown. The findings are best read as a mechanistic hypothesis worth testing further, not as support for off-label methylene blue use. The authors call for pharmacokinetic work, dosing optimization, and in vivo validation before any clinical application can be considered.
"Pre-treatment with MB protected HFSCs from GLP-1 RA-induced metabolic stress and premature cell death," the authors wrote, while emphasizing that the results "are based on in vitro cellular models and that further in vivo studies will be necessary before clinical applications can be established."
Source: Sadashivaiah K. Aging. 2026 May 5. Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration